Sponsors (2)
The bill improves drug-supply reliability and emergency responsiveness by mandating six-month reserves and boosting domestic production, but it raises federal costs, imposes compliance and inventory burdens on manufacturers, may leave some foreign dependencies, and could disrupt commercial arrangements.
Patients (including those with chronic conditions) and hospitals gain more reliable access to critical drugs because manufacturers and stockpiles must hold roughly six months of APIs and finished products, reducing routine shortages.
Hospitals and health systems can plan care better because HHS will publish a list of critical drugs and report biennially on program effectiveness and shortages.
Small manufacturers and state governments supporting production benefit from strengthened domestic manufacturing and surge capacity due to procurement preferences and funding, improving U.S. drug production resilience.
Taxpayers face increased federal spending because the bill authorizes $500 million for FY2026 and may require additional construction or contracting costs.
Small and other manufacturers will incur new compliance and inventory-holding costs to maintain six-month reserves and meet quality/eligibility rules, which could raise production costs or be passed to buyers.
Patients and hospitals may still face some foreign dependence because OECD-registered foreign suppliers could hold reserves abroad, leaving residual reliance on non-U.S. facilities.
Based on analysis of 2 sections of legislative text.
Requires HHS to contract for and maintain replenished domestic or OECD-based rolling reserves (typically six months) of critical drugs and APIs and permits allocation/transfers during emergencies.
Requires the Secretary of Health and Human Services to contract with eligible entities to create and maintain a rolling reserve of critical drugs and their active pharmaceutical ingredients (APIs) that have vulnerable supply chains, and to publish the list of those drugs and APIs. Contracted entities must hold either a six-month reserve (or another Secretary-determined reasonable quantity) of both API and finished product in an approved domestic facility or an approved facility in an OECD country, replenish those reserves from recently manufactured supplies, and produce drugs or APIs at the Secretary’s direction. The Secretary may direct transfers or allocation of API reserves during public health emergencies, natural disasters, or chemical/biological/radiological/nuclear threats, and must issue guidance within 180 days describing drug/API selection factors, entity eligibility criteria, and awardee requirements.
Introduced June 12, 2025 by Angela Craig · Last progress June 12, 2025